Mechanism of action of a tyrphostin, 3,4-dihydroxy-α-cyanothiocinnamamide, in breast cancer cell growth inhibition involves the suppression of cyclin B1 and the functional activity of cyclin B1/p34(cdc2) complex

Breast Cancer Research and Treatment

Volumn 44, Issue 1, 1997, Pages 47-56

  Faaland, Carol A ^a   Adhikarakunnathu, Sreedevi ^a   Thomas, Thresia ^a   Thomas, T J ^a,b  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Cyclins; Estrogen receptor; MCF 7 cells; p34(cdc2); Tyrphostin

Indexed keywords

3,4 DIHYDROXY ALPHA CYANOTHIOCINNAMAMIDE; CYCLIN B; HISTONE H1; PHOSPHOTRANSFERASE; PROTEIN TYROSINE KINASE; TYROSINE; TYRPHOSTIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DETERMINATION; ENZYME ACTIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PHOSPHORYLATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

BREAST NEOPLASMS; CDC2 PROTEIN KINASE; CELL CYCLE; CELL DIVISION; CYCLIN B; CYCLINS; ENZYME INHIBITORS; FEMALE; G1 PHASE; HUMANS; NITRILES; PHENOLS; PRECIPITIN TESTS; TUMOR CELLS, CULTURED; TYRPHOSTINS;

EID: 0030888656     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005765807923     Document Type: Article

References (53)

1. Yarden Y, Ullrich A: Growth factor receptor tyrosine kinases. Annu Rev Biochem 57: 443-478, 1988
2. Dobrusin EM, Fry DW: Protein tyrosine kinases and cancer. Annu Reports Med Chem 27: 820-832, 1992
3. Cohen B, Yoakim M, Piwnica-Worms H, Roberts TM, Schaffhausen BS: Tyrosine phosphorylation is a signal for the trafficking of pp85, an 85 kDa phosphorylated polypeptide associated with phosphatidylinositol kinase activity. Proc Natl Acad Sci USA 87: 4458-4462, 1990
4. Wilks AF: Structure and function of protein tyrosine kinases. Prog Growth Factor Res 2: 97-111, 1992
5. Bano M, Worland P, Kidwell WR, Lippman ME, Dickson RB: Receptor-induced phosphorylation by mammary-derived growth factor 1 in mammary epithelial cell lines. J Biol Chem 267: 10389-10392, 1992
6. Arteaga CL, Hurd SD, Dugger TC, Winner AR, Robertson JB: Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor alpha-pseudomonas exotoxin 40 fusion protein. Cancer Res 54: 4703-4709, 1994
7. Normanno N, Ciardiello F, Brandt R, Salomon DS: Epidermal growth factor-related peptides in the pathogenesis of human breast cancer. Breast Cancer Res Treat 29: 11-27, 1994
8. Workman P, Brunton VG, Robins D: Tyrosine kinase inhibitors. Sem Cancer Biol 3: 369-381, 1992
9. Burke TR: Protein-tyrosine kinase inhibitors. Drugs of the Future 17: 119-125, 1992
10. Yaish P, Gazit A, Gilon C, Levitzki A: Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 243: 933-935, 1983
11. Gazit A, Yaish P, Gilon C, Levitzki A: Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem 32: 2344-2352, 1989
12. Umezawa H, Imoto H, Sawa T, Isshiki K, Matsuda N, Uchida T, Iinuma H, Hamada KM, Takeuchi T: Studies on a new epidermal growth factor-receptor kinase inhibitor, erbstatin, produced by MH435-hF3. J Antibiotics 39: 170-173, 1986
13. Lyall RM, Zilberstein A, Gazit A, Gilon C, Levitzki A, Schlessinger J: Tyrphostins inhibit epidermal growth factor (EGF)-receptor tyrosine kinase activity in living cells and EGF-stimulated cell proliferation. J Biol Chem 264: 14503-14509, 1989
14. Faaland CA, Mermelstein FH, Hayashi J, Laskin JD: Rapid uptake of tyrphostin into A431 human epidermoid cells is followed hy delayed inhibition of epidermal growth factor (EGF)-stimulated EGF receptor tyrosine kinase activity. Mol Cell Biol 5: 2697-2703, 1991
15. Brunton VG, Lear MJ, Robins DJ, Williamson S, Workman P: Synthesis and antiproliferative activity of tyrphostins containing heteroaromatic moieties. Anti-Cancer Drug Design 9: 291-309, 1994
16. Ohmichi M, Pang L, Ribon V, Gazit A, Levitski A, Saltiel AR: The tyrosine kinase inhibitor tyrphostin blocks the cellular actions of nerve growth factor. Biochemistry 32: 4650-4658, 1993
17. Margolis B, Rhee SG, Felder S, Mervic M, Lyall R, Levitzki A, Ullrich A, Zilberstein A, Schlessinger J: EGF induces tyrosine phosphorylation of phospholipase C-II: a potential mechanism for EGF receptor signaling. Cell 57: 1101-1107, 1989
18. Ramdas L, McMurray JS, Budde RJA: The degree of inhibition of protein tyrosine kinase activity by tyrphostin 23 and 25 is related to their instability. Cancer Res 54:867-869, 1994
19. Aflalo E, Iftach S, Segal S, Gazit A, Priel E: Inhibition of topoisomerase I activity by tyrphostin derivatives, protein tyrosine kinase blockers. Mechanism of action. Cancer Res 54: 5138-5142, 1994
20. Stanwell C, Burke TR Jr, Yuspa SH: The erbstatin analogue methyl 2,5-dihydroxycinnamate cross-links proteins and is cytotoxic to normal and neoplastic epithelial cells by a mechanism independent of tyrosine kinase inhibition. Cancer Res 55: 4950-4956, 1995
21. Burger AM, Kaur G, Alley MC, Supko JG, Malspeis L, Grever MR, Sausville EA: Tyrphostin AG17, [3,5-di-tertbutyl-4-hydroxybenzylidene)-malononitrile], inhibits cell growth by disrupting mitochondria. Cancer Res 55: 2794-2799, 1995
22. Wolbring G, Hollenberg MD, Schnetkamp PPM: Inhibition of GTP-utilizing enzymes by tyrphostins. J Biol Chem 269: 22470-22472, 1994
23. Mazumder A, Gazit A, Levitzki A, Nicklaus M, Yung J, Kohlhagen G, Pommier Y: Effects of tyrphostins, protein kinase inhibitors, on human immunodeficiency virus type I integrase. Biochemistry 34: 15111-15122, 1995
24. Reddy KB, Mangold GL, Tandon AK, Yoneda T, Mundy GR, Zilberstein A, Osborne CK: Inhibition of breast cancer cell growth in vivo by a tyrosine kinase inhibitor. Cancer Res 52: 3636-3641, 1992
25. Wang TTY, Sathyamoorthy N, Phang JM: Molecular effects of genistein on estrogen receptor mediated pathways. Carcinogenesis 17: 271-275, 1996
26. Hunter T, Pines J: Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79: 573-582, 1994
27. Reed SI: The role of p34 kinases in the G1 to S phase transition. Annu Rev Cell Biol 8: 529-561, 1991
28. Murray AW, Kirschner MW: Cyclin synthesis drives the early embryonic cell cycle. Nature 339: 275-280, 1989
29. Lee MG, Nurse P: Complementation used to clone a human homolog of the fission yeast cell cycle control gene cdc2. Nature 327: 31-35, 1987
30. cdc2. Cell 58: 833-846, 1989
31. cdc2 protein kinase in vertebrates. EMBO J 10: 3321-3329, 1991
32. 2/M transitions of the cell cycle: identification of major phosphorylation sites. EMBO J 10: 305-316, 1991
33. Xiong Y, Connolly T, Beach D: Human D-type cyclin. Cell 65: 691-699, 1991
34. Sherr J: Mammalian G1 cyclins. Cell 73: 1059-1065, 1993
35. Hunter T: Braking the cycle. Cell 75: 839-841, 1993
36. Doree M: Control of M-phase by maturation promoting factor. Curr Opin Cell Biol 2: 269-273, 1990
37. Ohtsubo M, Roberts JM: Cydin-dependent regulation of G1 in mammalian fibroblasts. Science 259: 1908-1911, 1993
38. Thomas T, Thomas TJ: Regulation of cyclin B1 by estradiol and polyamines in MCF-7 breast cancer cells. Cancer Res 54: 1077-1084, 1994
39. Keyomarsi K, Pardee A: Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci USA 90: 1112-1116, 1993
40. Jiang SY, Wolf DM, Yingling JM, Chang C, Jordan VC: An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Mol Cell Endocrinol 90: 77-86, 1992
41. Burton K: A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J 62: 315-323, 1956
42. Faaland CA, Laskin JD, Thomas TJ: Inhibition of epidermal growth factor (EGF)-stimulated EGF receptor tyrosine kinase activity in A431 human epidermoid carcinoma cells by polyamines. Cell Growth Different 6: 115-121, 1995
43. Ottenhoff-Kalff A, Rijksen G, van Beurden EA, Hennipman A, Michels AA, Stall GE: Characterization of protein tyrosine kinases from human breast cancer: involvement of the src oncogene product. Cancer Res 52: 4773-4778, 1992
44. Gill GN, Lazar CS: Role of epidermal growth factor-stimulated protein kinase in control of proliferation of A431 cells. Nature 293: 305-307, 1981
45. Haigler H, Ash JF, Singer SJ, Cohen S: Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells A431. Proc Natl Acad Sci USA 75: 3317-3321, 1978
46. Carpenter G, Zendegui JG: Epidermal growth factor, its receptor and related proteins. Exper Cell Res 164: 1-10, 1986
47. Azevedo WFD, Mueller-Dieckmann HJ, Schulze-Gahmen U, Worland PJ, Sausville E, Kim S-H: Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci USA 93: 2735-2740, 1996
48. Johnson LN, Noble MEM, Owen DJ: Active and inactive protein kinases: structural basis for regulation. Cell 85: 149-258, 1996
49. Kiang DT, Frenning DH, Goldman AI, Aslensa VF, Kennedy BJ: Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. N Engl J Med 229: 1330-1334, 1984
50. Manni A, Pearson O: Antiestrogen-induced remission in premenopausal women with stage IV breast cancer. Cancer Treat Rep 64: 779-785, 1980
51. Clarke R, Dickson RB, Lippmann ME: Hormonal aspects of breast cancer: Growth factors, drugs and stromal interactions. Crit Rev Oncology-Hematology 12: 1-23, 1992
52. Henderson BE, Ross R, Bernstein L: Estrogens as a cause of human cancer. Cancer Res 48: 246-253, 1988
53. Levitzki A: Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. FASEB J 6: 3275-3282, 1992